|Bid||26.38 x 51100|
|Ask||26.42 x 25600|
|Day's range||26.31 - 26.66|
|52-week range||22.89 - 30.08|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||42.54|
|Forward dividend & yield||0.20 (0.75%)|
|Ex-dividend date||10 Feb 2021|
|1y target est||12.43|
With big growth trending for CPAP machines and related products, the two biggest names in sleep apnea are expected to prosper this year.
In this episode of Industry Focus: Wildcard, join Motley Fool contributor Brian Feroldi and host Emily Flippen as they talk about three companies trying to treat sleep apnea: ResMed (NYSE: RMD), Inspire Medical (NYSE: INSP), and Vivos Therapeutics (NASDAQ: VVOS). To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Today is Wednesday, March 24th, and I am your host, Emily Flippen.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details: • Location: http://investor.resmed.com • Date: Thursday, April 29, 2021 • Time: 1:30 p.m. PDT / 4:30 p.m. EDT • International: London, Thursday, April 29, 9:30 p.m. BST Sydney, Friday, April 30, 6:30 a.m. AEST Please note that ResMed does not use outside phone lines to access the earnings call.A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from April 29 until May 13 at: U.S.: +1 800.585.8367International: +1 416.621.4642Conference ID: 7757454 About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed. For investors Amy Wakeham +1 858.836.5000 firstname.lastname@example.org For mediaJayme Rubenstein+1 email@example.com